Jaguar Health enters license, commercialization agreement with Quadri Pharma

Napo Pharmaceuticals has entered a revenue sharing license and commercialization agreement with Quadri Pharmaceuticals Store that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for the rare disease indications of microvillus inclusion disease, other congenital diarrheal disorders, and short bowel syndrome with intestinal failure for a powder formulation of crofelemer for oral solution in multiple Middle East countries, following regulatory approval to market crofelemer for these indications. In addition, the Agreement grants Quadri Pharma exclusive rights to distribute the powder formulation of crofelemer for the specified indications through Named Patient Programs in the specified Middle East countries following regulatory guidelines.